CGP-53353

• Description :

  CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients[1].

• CAS Number :

  [145915-60-2]

• Product Name Alternative :

  DAPH-7

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis; PKC

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/cgp-53353.html

• Concentration :

  10mM

• Purity :

  98.87

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C1NC(C2=C1C=C(NC3=CC=C(F)C=C3)C(NC4=CC=C(F)C=C4)=C2)=O

• Molecular Formula :

  C20H13F2N3O2

• Molecular Weight :

  365.33

• References & Citations :

  [1]Yamamoto M, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279 (3) :C587-C595.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PKCβ